Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 1154.34%.

  • Beam Therapeutics' EBITDA Margin fell 4969800.0% to 1154.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 746.15%, marking a year-over-year decrease of 7061600.0%. This contributed to the annual value of 593.01% for FY2024, which is 5587200.0% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' EBITDA Margin is 1154.34%, which was down 4969800.0% from 1210.03% recorded in Q2 2025.
  • Beam Therapeutics' EBITDA Margin's 5-year high stood at 45.99% during Q4 2023, with a 5-year trough of 3359583.33% in Q1 2021.
  • For the 5-year period, Beam Therapeutics' EBITDA Margin averaged around 244409.41%, with its median value being 696.62% (2022).
  • In the last 5 years, Beam Therapeutics' EBITDA Margin tumbled by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2022.
  • Beam Therapeutics' EBITDA Margin (Quarter) stood at 126.84% in 2021, then plummeted by -42bps to 180.19% in 2022, then soared by 126bps to 45.99% in 2023, then tumbled by -761bps to 304.1% in 2024, then tumbled by -280bps to 1154.34% in 2025.
  • Its EBITDA Margin stands at 1154.34% for Q3 2025, versus 1210.03% for Q2 2025 and 1469.73% for Q1 2025.